870822-92-7

Upstream product

• 870822-89-2 tert-butyl 2-{(1S)-1-[4-(ethoxycarbonyl)phenyl]ethyl}hydrazinecarboxylate 
• 76-05-1 trifluoroacetic acid 

Downstream Products

• 934495-06-4 ethyl 4-((1S)-1-{3-[2-methoxy-5-(trifluoromethyl)phenyl]-5-oxo-4,5-dihydro-1H-pyrazol-1-yl}ethyl)benzoate 
• 870823-15-7 ethyl 4-((1S)-1-{3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-oxo-4,5-dihydro-1H-pyrazol-1-yl}ethyl)benzoate 
• 870823-08-8 ethyl 4-{(1S)1-[3-(3,5-dichlorophenyl)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]ethyl}benzoate 

Relevant academic research and scientific papers

Pyrazole derivatives, compositions containing such compounds and methods of use

Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes

Pyrazole derivatives, compositions containing such compounds and methods of use

Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.